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Abstract: Ki67 is a key biomarker associated with cancer cell proliferation and poor prognosis. We previously evalu-
ated the diagnostic potential of quantitatively measured Ki67 mRNA levels in formalin-fixed paraffin-embedded 
(FFPE) cervical cancer tissue samples. In the present study, we continued this avenue of research using quantita-
tive reverse transcriptase PCR (RT-qPCR) to measure Ki67 mRNA levels in FFPE cervical tissues and performed an 
assessment with each clinical prognostic factor of patients. We obtained 190 FFPE cervical tissue samples that 
comprised of 80 squamous cell carcinoma (SCC), 10 adenocarcinoma (ADC), 30 HSIL, 30 LSIL, and 40 normal 
cervical tissue samples. And using this assay, we also evaluated the predictive value of Ki67 in cases with a low-
grade squamous intraepithelial lesion (LSIL) and those with a high-grade squamous intraepithelial lesion (HSIL).
As a result, Ki67 mRNA levels were increased in SCC and ADC cervical cancer tissues (n = 90) compared to those 
in normal cervical tissues (n = 40) (P < 0.001). The diagnostic validity of the Ki67 mRNA assay was evaluated and 
demonstrated a sensitivity of 93.3% (95% confidence interval (CI) = 86.1 to 97.5) and a specificity of 97.5% (95% 
CI = 86.8 to 99.9). Ki67 mRNA positivity was 93.3% for cervical cancer, 40.0% for HSIL, 13.3% for LSIL, and 2.5% 
for normal tissue samples. Furthermore, we found that high levels of Ki67 mRNA expression in cervical cancer were 
associated with lymph node status (P = 0.01). In conclusion, Ki67 mRNA assay can provide an additional accurate 
approach for molecular diagnosing cervical cancer, and also predict prognosis of cervical cancer depending on LSIL 
and/or HSIL status.
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Introduction
Cervical cancer is the third most common 
malignancy in women globally and one of the 
leading causes of morbidity and mortality in 
women worldwide. The World Health Orga- 
nization estimates that approximately 527,600 
women are newly diagnosed and there are 
265,700 deaths from cervical cancer every 
year [1]. Human papillomavirus (HPV) is a major 
cause of cervical cancer and is the most com-
mon sexually transmitted pathogen among 
women and men [2]. Therefore, the detection of 
HPV is routinely performed in exfoliated infect-
ed cervical cells or tissues of patients with 
cervical cancer or patients with precancerous 
lesion [3-7].
However, most high-risk HPV infections resolve 
spontaneously within 1 to 2 years [2]. Several 
studies have investigated the molecular mech-
anisms underlying cervical cancer carcinogen-
esis to identify potential diagnostic or prognos-
tic biomarkers for cervical cancer [8-11]. For 
example, putative molecular markers such as 
p16, p53, and Ki67 have been identified in cer-
vical carcinogenesis. Their respective coding 
genes and proteins have been characterized, 
and their roles in the process have been stud-
ied with the aim of improving diagnosis and 
treatment of cervical cancer.
Several studies found that among these differ-
ent markers, immunohistochemical (IHC) stain-
ing of Ki67 was an effective method for the 
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prognosis of different tumor types [12-15]. 
Ki67 is associated with cell cycle activity and is 
expressed at varying levels during G1, S, G2, 
and M phases, but is not expressed in G0 [10, 
16]. In our previous study, we demonstrated 
the potential diagnostic value of Ki67 in cervi-
cal cancer by quantitatively measuring Ki67 
mRNA levels in formalin-fixed paraffin-embed-
ded (FFPE) cervical cancer tissue samples [17]. 
A purpose of the current study is to investigate 
the relationship between Ki67 mRNA level and 
clinicopathological measures of patients with 
cervical cancer.
Low-grade squamous intraepithelial lesion 
(LSIL) and high-grade squamous intraepithelial 
lesion (HSIL) are important precancerous 
courses in the development of cervical cancer, 
but their carcinogenesis is not well-known [16, 
18, 19]. Cox et al, performed a meta-analysis 
and concluded that the likelihood of progres-
sion from LSIL to HSIL was approxima- 
tely 10% within 2 years [20]. However, there is 
went pathological testing at the Department of 
Pathology, Yonsei University Wonju Severance 
Christian Hospital between January 2010 and 
December 2014. This study was approved by 
the Institutional Ethics Committee of Yonsei 
University Wonju College of Medicine (approval 
no. CR315052), and all subjects were provided 
written informed consent. Of the 190 FFPE 
tissue samples collected, 40 (21.1%) were 
normal, 30 (15.8%) were LSIL, 30 (15.8%) were 
HSIL, 10 (5.3%) were adenocarcinoma (ADC), 
and 80 (42.1%) were squamous cell carcinoma 
(SCC) (Table 1). Using a prior grading system for 
diagnosis, we categorized grade 1 cervical 
intraepithelial neoplasia (CIN 1) tissue as LSIL 
and grade 3 cervical intraepithelial neoplasia 
(CIN 3) tissue as HSIL. FFPE normal tissue 
samples included 40 chronic cervicitis speci-
mens obtained from patients who underwent 
a hysterectomy for other benign gynecological 
diseases such as leiomyoma and adeno- 
myosis.
Table 1. Clinical characteristics of patients
Cancer (n = 90)
n (%)
HSIL (n = 30)
n (%)
LSIL (n = 30)
n (%)
Normal (n = 40)
n (%)
Age
    ≤50 years 41 (45.6) 23 (76.7) 20 (66.7) 24 (60.0)
    >50 years 49 (54.4) 7 (23.3) 10 (33.3) 16 (40.0)
HPV DNA chip 
    Negative 7 (7.8) 1 (3.3) 11 (36.7)
    Positive 66 (73.3) 21 (70.0) 10 (33.3)
    Unknown* 17 (18.9) 8 (26.7) 9 (30.0)
Histology 
    SCC 80 (88.9)
    ADC 10 (11.1)
FIGO stage
    < IIB 34 (37.8)
    ≥ IIB 43 (47.8)
    Unknown 13 (14.4)
Lymph nodes 
    Negative 37 (41.1)
    Positive 37 (41.1)
    Unknown 16 (17.8)
Tumor size
    ≤4 cm 43 (47.8)
    >4 cm 33 (36.7)
    Unknown 14 (15.5)
ADC, adenocarcinoma; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-
grade squamous intraepithelial lesion; HPV, human papillomavirus; SCC, squamous 
cell carcinoma. *Unknown stands for cases referred to other institution after biopsy 
without any baseline study.
no accurate method or 
approach to identify which 
patients with LSIL will 
progress to HSIL. Therefore, 
a better understanding of 
cervical cancer progression 
is necessary for improved 
management of patients 
with either LSIL or HSIL.
In this study, we evaluated 
the discriminatory power of 
a Ki67 mRNA assay using 
quantitative reverse tran-
scriptase PCR (RT-qPCR). 
We determined threshold 
cutoff for the diagnosis of 
cervical cancer using one 
hundred and ninety FFPE 
cervical cancer tissues and 
studied their clinical rele-
vance. Additionally, the pre-
dictive prognostic value of 
Ki67 mRNA was assessed 
in cases with LSIL or HSIL.
Materials and methods
Patients and samples
We retrospectively obtained 
190 FFPE cervical tissues 
from patients who under-
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Deparaffinization of FFPE tissue and total RNA 
extraction
Three 10-μm sections from each paraffin block 
of cervical tissue were used for total RNA 
extraction. Extractions were performed using 
the Qiagen RNeasy FFPE mini kit (Qiagen, 
Hilden, Germany) according to the manufactur-
er’s protocol. RNA purity and concentration 
were determined by measuring absorbance at 
260 nm and 280 nm using a spectrophotome-
ter (Infinite 200, Tecan, Salzburg, Austria). All 
RNA preparation and handling was performed 
in a laminar flow hood under RNase-free condi-
tions. Isolated RNA was stored at -70°C.
cDNA synthesis
Complementary DNA (cDNA) was synthesized 
using the M-MLV Reverse Transcriptase kit 
(Invitrogen, Carlsbad, CA, USA) and random 
hexamers (Invitrogen) according to the manu-
facturer’s recommendations. Briefly, 10 μL of 
total RNA was added to a master mix contain-
ing 10 mM dNTPs at neutral pH, 0.25 μg ran-
dom hexamers, and 5-μL DEPC-treated water. 
Reactions were incubated at 65°C for 5 min 
and chilled on ice. A mixture of 4 μL 5× First-
Strand Buffer, 2 μL 0.1 M dithiothreitol, and 1 
μL M-MLV reverse transcriptase (RT) was 
added, and cDNA synthesis was synthesized at 
25°C for 10 min, followed by 37°C for 50 min, 
and 70°C for 15 min.
Ki67 mRNA RT-qPCR assay
Quantitative real-time PCR amplification of the 
OPTIMYGENE Ki67 mRNA assay (Optipharm, 
Osong, Republic of Korea) was performed in 
10 μL 2× Thunderbird probe qPCR mix (Toyobo, 
Osaka, Japan), 3 μL primer and TaqMan probe 
mixture, 2 μL template cDNA, and distilled 
water (DW) to a final volume of 20 μL per 
sample. Positive and negative controls were 
included. No-template controls were included 
in each run and consisted of sterile DW instead 
of template DNA. PCR cycling was 95°C for 3 
min, followed by 40 cycles of 95°C for 3 sec-
onds, and 55°C for 30 seconds. mRNA levels 
were quantified by determining the cycle thre- 
shold (CT), which is defined as the number of 
PCR cycles required for fluorescence to exceed 
a value significantly higher than that of the 
background fluorescence. To avoid false nega-
tives because of mRNA degradation, glyce- 
raldehyde-3-phosphate dehydrogenase (GAP- 
DH) was used as an internal control. The 
amount of Ki67 mRNA was determined using 
the comparative CT method (ΔΔCT method) [21], 
Table 2. Ki67 mRNA expression in matched non-cancerous and cancerous lesions
Age BMI Cytology Histology 
Ki67 mRNA expression
P value
Non-cancerous lesion Cancerous lesion Fold change
P001 62 33.3 ADC ADC 0.06 0.22 3.67 P = 0.0005*
P002 39 22.1 ASCUS SCC 0.26 22.32 85.85
P003 41 25.8 SCC SCC 0.04 7.01 175.25
P004 49 20.5 SCC SCC 0.04 5.9 162.10
P005 36 22.8 ADC ADC 2.62 38.85 14.82
P006 30 21.6 HSIL SCC 0.64 1.18 1.84
P007 40 16.4 SCC SCC 3.12 35.02 11.22
P008 57 21.4 ADC ADC 0.19 11.79 62.05
P009 30 19.6 ADC ADC 0.01 4.35 435.00
P010 57 22.7 SCC SCC 0.19 53.34 280.74
P011 46 20.7 SCC SCC 3.43 131.6 38.37
P012 35 27.6 HSIL SCC 0.25 24.59 98.36
P013 42 21.9 SCC SCC 1.19 39.95 33.57
P014 57 26.2 ADC ADC 0.2 34.54 172.70
P015 67 26.6 HSIL SCC 0.03 35.02 1167.33
P016 65 27.9 SCC SCC 0.28 29.86 106.64
*Ki67 mRNA levels were higher in canceroustissuelesion than that found in matched Non-cancerous tissuelesion (Wilcoxon 
matched-pairs test). ADC, adenocarcinoma; ASCUS, Atypical squamous cells of undetermined significance; BMI, body mass 
index; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma.
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was normalized to the internal housekeeping 
gene GAPDH using the following equation: 
ΔΔCT = (ΔCT [target sample] - ΔCT [normal 
sample]).
Statistical analysis
Statistical analyses were performed using 
GraphPad Prism v5.02 (GraphPad, La Jolla, CA, 
USA) and SPSS (Statistical Package for the 
Social Sciences) v23.0 (SPSS Inc., Chicago, IL, 
USA). The Wilcoxon matched-pairs test was 
used to compare nonparametric-matched sam-
ples, and the Student’s t-test and 95% confi-
dence interval (CI) were used to determine sta-
tistical significance. Receiver operating charac-
teristic (ROC) curves were used to predict cut-
off values of the marker. Sensitivity and speci-
ficity were calculated using MedCalc v12.5 
(MedCalc software, Ostend, Belgium). The 
Pearson’s chi-square test was used to analyze 
associations between the positivity of Ki67 
mRNA expression and histologically diagnosed 
samples. For all tests, a P value < 0.05 was 
considered statistically significant.
Results
Patient characteristics
Patient characteristics are summarized in Table 
1. One hundred and ninety FFPE tissue sam-
ples were used in this study of which 90 (47.3%) 
were cancer, 30 (15.8%) were HSIL, 30 (15.8%) 
were LSIL, and 40 (21.1%) were normal sam-
ples. Especially, for cervical cancer cases, data 
on histology, FIGO stage, tumor size, and lymph 
node positivity were retrospectively reviewed 
from patient medical records (Table 1). Among 
90 cases of cervical cancer, 80 (88.9%) cases 
were diagnosed as SCC, 43 (47.8%) cases were 
more than FIGO stage IIB, 33 (36.7%) cases 
had more than 4 cm of tumor size, and 37 
(41.1%) cases showed positive lymph nodes. 
Ki67 mRNA levels for matched FFPE cancer-
ous and non-cancerous tissues
To evaluate the effectiveness of the Ki67 mRNA 
assay, matched FFPE cancerous and non-can-
cerous tissues from 16 cervical cancer patients 
were tested. Using ∆∆CT to determine mRNA 
levels in matched tissue samples, we found 
that levels of Ki67 mRNA in cancer tissues 
were higher than those in matched normal tis-
sues (P = 0.0005). The Ki67 mRNA levels in 
Figure 1. Receiver operating characteristics (ROC) 
curve analysis. A. The area under the ROC curve 
(AUC) was 0.97 (95% CI = 0.94 to 1.00, P < 0.001). 
B. Ki67 mRNA levels were significantly higher in 
FFPE cancer tissues compared to that found in FFPE 
normal tissues (t-test, P < 0.001) using a diagnostic 
threshold of 5 (shown as a horizontal dotted line). 
***P < 0.001.
Table 3. Sensitivity, specificity, NPV, and PPV 
of Ki67 mRNA levels in cervical cancer and 
normal tissues
Ki67 mRNA RT-qPCR 
assay (n = 130) 95% CI
Sensitivity 93.3% 86.1-97.5
Specificity 97.5% 86.8-99.9
PPV 98.8% 93.6-100.0
NPV 86.7% 73.2-95.0
PPV, positive predictive value; NPV, negative predictive 
value; CI, confidence interval.
measuring mRNA relative to a reference gene 
using CFX Manager Software v1.6 (Bio-Rad, 
Hercules, CA, USA). The amount of Ki67 mRNA 
Ki67 mRNA expression in cervical cancer
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normal tissues ranged from 0.01 to 3.43 com-
pared to those in cancer tissues ranged from 
0.22 to 131.60. The Ki67 mRNA levels in cervi-
cal cancer tissues were 1.84- to 1167.33-fold 
higher compared to levels found in normal tis-
sues (Table 2).
Diagnostic value of Ki67 for cervical cancer
ROC curve analysis was performed to deter-
mine the optimal diagnostic cutoff value for the 
assay to discriminate normal tissues from 
those with cervical cancer. Ki67 mRNA levels 
were analyzed in 90 FFPE cancer tissues and 
40 FFPE normal tissues, and found that the 
area under the ROC curve (AUC) was 0.97 (95% 
CI = 0.94 to 1.00, P < 0.001, Figure 1A). We 
also found that the levels of Ki67 mRNA in cer-
vical cancer tissues were significantly increased 
compared to that found in normal cervical tis-
sues. Based on these findings, we set a diag-
nostic cutoff (threshold) of 5 (P < 0.001, Figure 
1B). Using a threshold of 5, the assay had a 
sensitivity of 93.3% (95% CI = 86.1 to 97.5), a 
specificity of 97.5% (95% CI = 86.8 to 99.9), a 
positive predictive value of 98.8% (95% CI = 
93.6 to 100.0), and a negative predictive value 
of 86.7% (95% CI = 73.2 to 95.0) (Table 3).
Figure 2. Box and whisker plots of Ki67 mRNA levels in histologically diagnosed FFPE cervical tissues. Ki67 mRNA 
levels in FFPE normal tissues were significantly lower than that found in LSIL, HSIL, and cancer tissues (t-test, P < 
0.0001). ***P < 0.001, *P < 0.05.
Table 4. Association between Ki67 mRNA expression levels and histologically diagnosed cervical 
grades
Ki67 mRNA RT-qPCR assay
Chi-square (df, P value)
Ki67-Positive Cases n (%)
Ki67 expression levels
Median (Min-Max)
Normal (n = 40) 1 (2.5) 0.8 (0.0-5.6) Reference
LSIL (n = 30) 4 (13.3) 2.2 (1.1-7.2) 7.4, P < 0.0001
HSIL (n = 30) 12 (40.0) 4.5 (0.5-13.7) 17.9, P < 0.0001
Cancer (n = 90) 84 (93.3) 26.2 (0.2-131.6) 100.9, P < 0.0001
LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; SD: Standard deviation.
Ki67 mRNA expression in cervical cancer
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Ki67 mRNA levels in histologically diagnosed 
FFPE cervical tissues
Ki67 mRNA levels were evaluated with histo-
logically diagnosed cervical tissues to deter-
mine whether Ki67 mRNA levels discriminated 
between normal, LSIL, HSIL, and cancer tis-
sues. Ki67 mRNA levels were ranged from 0.0 
to 5.6 (median 0.8) in 40 normal tissues, from 
1.1 to 7.2 (2.2) in 30 LSIL tissues, from 0.5 to 
13.7 (4.5) in 30 HSIL tissues, and from 0.2 to 
131.6 (26.2) in 90 cancer tissues. The highest 
Ki67 mRNA levels were expressed in cancer tis-
sues, with progressively lower but still elevated 
levels were checked in HSIL and LSIL tissues 
compared to the levels in normal tissues (P < 
0.0001) (Figure 2 and Table 4). Using a cutoff 
of 5, positivity for Ki67 was 2.5% (1/40 cases) 
for normal, 13.3% (4/30 cases) for LSIL, 40.0% 
(12/30 cases) for HSIL, and 93.3% (84/90 
cases) for cancer. We found that this Ki67 
mRNA assay using a diagnostic threshold of 5 
discriminated between normal and abnormal 
cervical lesions (P < 0.001) (Table 4).
Ki67 mRNA expression in relation to clinical 
prognostic parameters in cervical cancer tis-
sues
The median value of Ki67 mRNA levels in cervi-
cal cancer tissues was 26.2. To determine 
whether there was an association between 
Ki67 mRNA levels in cervical cancer tissues 
and clinical prognostic parameters, specifically, 
age, HPV status, FIGO stage, lymph node posi-
tivity, and tumor size, the Ki67 mRNA levels-
were divided into two groups: a low Ki67 (below 
the median Ki67 mRNA level) group and a high 
Ki67 (above the median Ki67 mRNA level) 
group. Among the clinical prognostic parame-
ters of cervical cancer,lymph node metastasis 
showed statistically significant relation with a 
high Ki67 group (P = 0.01) (Table 5).
Discussion
Cervical cancer is a leading cause of cancer 
mortality in 35-55 year old women worldwide. 
To avoid unnecessary treatment of transient 
HPV infections and related benign lesions, the 
optimal screening strategy for cervical cancer 
should efficiently and accurately identify pre-
cursor lesions that will progress to an invasive 
cancer [22]. The purpose of the present study 
was to evaluate Ki67 mRNA expression levels 
with histological grades to identify and under-
stand the relationship between the Ki67 mRNA 
assay and clinicopathological parameters of 
cervical cancer, and assess the performance 
evaluation of the assay as a diagnostic test for 
the detection of cervical cancer.
Our study compared Ki67 mRNA levels between 
matched cancerous and noncancerous tissues 
from 16 patients diagnosed with cervical SCC 
or ADC, and found that there were significant 
differences in mRNA levels between matched 
FFPE tissue samples (P = 0.0005) (Figure 1). In 
fact, comparing to normal tissues, Ki67 mRNA 
expression levels in cancer tissues enabled 
their discrimination regardless of whether they 
were ADC or SCC. Yamamoto et al found that 
Ki67 mRNA expression levels were informative 
as a Ki67-labeling index in patients with breast 
cancer [8]. Taking a cue from this, in cervical 
cancer, this Ki67 mRNA assay was validated as 
adiscriminative marker.
Using 90 cervical cancer and 40 normal FFPE 
tissue samples, we studied this Ki67 mRNA 
assay accurately discriminated between cervi-
cal cancer and normal tissues with a high sen-
sitivity of 93.3% (95% CI 86.1 to 97.5) and a 
high specificity of 97.5% (95% CI 86.8 to 99.9) 
(Table 3). Several studies have demonstrated 
that Ki67 expression using immunoquantifica-
tion can provide greater discrimination not only 
Table 5. Ki67 mRNA expression correlated 
with clinical parameters in 90 cervical cancer 
patients
Ki67 mRNA expression
Number 
of cases
Low (Ki67 
< 26.2)
High (Ki67 
≥ 26.2)
P 
value
Age (years)
    ≤50 years 41 18 23 0.92
    >50 years 49 21 28
HPV DNA chip
    Negative 7 2 5 0.48
    Positive 66 28 38
FIGO stage
    < IIB 34 18 16 0.68
    ≥ IIB 43 17 26
Lymph node
    Negative 37 21 16 0.01
    Positive 37 12 25
Tumor size
    < 4 cm 43 23 22 0.30
    ≥ 4 cm 33 13 20
Ki67 mRNA expression in cervical cancer
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between normal and cancer tissues but also 
between LSIL and HSIL. And the reported aver-
age positivity rates found in normal, LSIL, and 
HSIL were 7.9%, 49%, and 90%, respectively 
[11, 23]. Similarly, in our study, positivity rates 
of Ki67 mRNA expression were 2.5%, 13.3%, 
and 40.0% in normal, LSIL, and HSIL respec-
tively. Moreover, the positivity rates of Ki67 
mRNA expression in cancer was 93.3%, and 
these were statistically significant (P < 0.001) 
(Table 4).
We also found that increased Ki67 mRNA 
expression in cancer samples was significantly 
higher than that found in normal, LSIL, and 
HSIL samples (Figure 2). Since about 10% of 
cases with LSIL progress to HSIL, cytological 
and/or histological follow-up are more fre-
quently needed in LSIL patients with tendency 
of disease progression. Chen et al and Zhou et 
al were attempt to predict progression using 
Ki67 immunocytochemistry and immunohisto-
chemistry tests and showed similar results that 
distinguishing LSIL and HSIL [24, 25]. In addi-
tion to burdening the healthcare system, the 
challenge of using such a broad screening 
approach is that it reduces overtreatment for 
follow-up in patients with LSIL, the majority of 
who do not progress to HSIL. 
Through clinicopathological prognostic param-
eter analysis separating patients into high Ki67 
expression (median ≥ 26.2) and low Ki67 
expression (median < 26.2) groups, lymph 
node positivity was associated with Ki67 mRNA 
levels (Table 5). Shokouh studied that Ki67 IHC 
was correlated to lymph node status in breast 
cancer [9]. Yang et al showed lymph node 
metastasis and immunohistochemical markers 
Ki67 correlated for the predicting lymph node 
metastasis in endometrial cancer [26]. Cervical 
cancer in this study as well as breast and endo-
metrial cancer in other studies also showed the 
interrelation of high Ki67 could be associated 
with lymph node positivity. 
Previous studies demonstrated that IHC stain-
ing of Ki67 may be used to complement HPV 
testing [27, 28]. Because of HPV screening pro-
grams, HPV infection status is widely tested, 
but there are no predictors to determine the 
risk of high-risk HPV infection causing progres-
sion to cancer. We demonstrated that Ki67 
mRNA assay can provide an additional accu-
rate approach for molecular diagnosing cervi-
cal cancer, and also predict prognosis of cervi-
cal cancerdepending on LSIL and/or HSIL 
status.
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